CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Douglas Kerr, M.D., Ph.D., to its board of directors. Dr. Kerr currently serves as chief medical officer at Generation Bio and has previously held leadership roles at Shire and Biogen, where he served as director of the ALS Innovation Initiative and led the development of the first FDA-approved medicine for spinal muscular atrophy.

“I am thrilled to welcome Doug as he joins our impressive Board made up of veteran biotechnology leaders, clinicians and science advisors within the industry,” said Philip Vickers, Ph.D., president and chief executive officer of Faze. “Doug has deep clinical and biological expertise as a neurologist, as well as a wealth of experience bringing innovative, first-in-class medicines through development and to market. He will be an incredible asset to Faze as we advance our mission to leverage the biology of biomolecular condensates to deliver new medical breakthroughs.”

Prior to joining Generation Bio, Dr. Kerr served as vice president and global development team lead for neurology at Shire, overseeing development and strategy across multiple clinical programs. Before joining Shire, Dr. Kerr held a variety of leadership roles at Biogen, including senior director of corporate strategy and portfolio management. At Biogen, Dr. Kerr was also director of the ALS Innovation Initiative and served as global medical lead for spinal muscular atrophy (SMA), leading to the approval of the first treatment for SMA. Dr. Kerr is currently a board member of Triplet Therapeutics and the Transverse Myelitis Association. In addition, he is chair of the science and medicine committee of CureSMA and serves on the scientific advisory committee of the Myotonic Dystrophy Foundation. Dr. Kerr received his B.A. from Princeton University and his M.D./Ph.D. from Jefferson Medical College. He obtained his MBA from Northeastern University School of Business.

“Faze is built on pioneering insights into the biology of biomolecular condensates and has the potential to create fundamentally new medicines for challenging diseases,” said Dr. Kerr. “I look forward to contributing to the Faze team as a board member as the company works to advance innovative therapeutics to the clinic and ultimately to patients.”

About Faze Medicines
Faze Medicines is a biotechnology company harnessing the groundbreaking new science of biomolecular condensates to create medical breakthroughs. Faze was founded by renowned scientific leaders in the field of biomolecular condensates and is supported by a world-class syndicate of investors including Third Rock Ventures, Novartis Venture Fund, Eli Lilly and Company, AbbVie Ventures, Invus, Catalio Capital Management, Casdin Capital and Alexandria Venture Investments. For more information, visit fazemed.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005370/en/